Bruker (BRKR) Cash & Equivalents (2010 - 2026)

Bruker's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• Quarterly Cash & Equivalents fell 27.58% year-over-year to $133.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $133.4 million (down 27.58% YoY) and the FY2025 annual result came in at $298.8 million, up 62.92% from the prior year.
• Cash & Equivalents was $133.4 million for Q1 2026 at Bruker, down from $298.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $816.1 million in Q1 2022 and bottomed at $92.0 million in Q2 2025.
• A 5-year average of $392.8 million and a median of $340.1 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 70.48% — and 2025, when it soared 97.91%.
• Bruker's Cash & Equivalents stood at $645.5 million in 2022, then slipped by 24.35% to $488.3 million in 2023, then tumbled by 62.44% to $183.4 million in 2024, then soared by 62.92% to $298.8 million in 2025, then sank by 55.35% to $133.4 million in 2026.
• Business Quant data shows BRKR's Cash & Equivalents at $133.4 million in Q1 2026, $298.8 million in Q4 2025, and $293.1 million in Q3 2025.